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Background: Seminomas have been rarely associated with malignant hypercalcemia. The responsible mechanism
of hypercalcemia in this setting has been described to be secondary to 1,25-dihydroxyvitamin D secretion. The
relationship with PTHrP has not been determined or studied.
The aim of this study is to describe and discuss the case and the pathophysiological mechanisms involved in a
malignant hypercalcemia mediated by 1,25-dihydroxyvitamin D and PTHrP cosecretion in a patient with seminoma.
Case presentation: A 35-year-old man was consulted for assessment and management of severe hypercalcemia
related to an abdominal mass. Nausea, polyuria, polydipsia, lethargy and confusion led him to the emergency
department. An abdominal and pelvic enhanced CT confirmed a calcified pelvic mass, along with multiple retroperitoneal
lymphadenopathy. Chest x-ray revealed “cannon ball” pulmonary metastases. The histopathology result was
consistent with a seminoma. Serum calcium was 14.7 mg/dl, PTH was undetectable, 25-dihydroxyvitamin D was
within normal values and PTHrP and 1,25-dihydroxyvitamin were elevated (35.0 pg/ml, and 212 pg/ml, respectively). After
the first cycle of chemotherapy with bleomycin, etoposide and cisplatin, normocalcemia was restored. Both PTHrP and
1,25-dihydroxyvitamin D, dropped dramatically to 9.0 pg/ml and 8.0 pg/ml, respectively.
Conclusion: The association of seminoma and malignant hypercalcemia is extremely rare. We describe a case of a patient
with a seminoma and malignant hypercalcemia related to paraneoplastic cosecretion of 1,25-dihydroxyvitamin D and
PTHrP. After successful chemotherapy, calcium, PTHrP and 1,25-Dihydroxyvitamin D returned to normal values.
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Malignant hypercalcemia is the most common paraneo-
plastic syndrome occurring in 20-30% of patients with
cancer [1]. It usually has an ominous prognosis, with
a mortality of 50% within the next 30 days [2]. Both
solid and hematologic malignancies have been associated
with this syndrome; the most frequent etiologies being
multiple myeloma, lung and breast cancer [3]. Four
mechanisms of hypercalcemia in malignancy have been* Correspondence: renerodriguez@investigacion-meduanl.com
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article, unless otherwise stated.described: local osteolysis, parathyroid hormone related-
protein (PTHrP) mediated, 1,25-dihydroxyvitamin D (1,25
(OH)2D3, calcitriol) secretion, and ectopic parathyroid
hormone (PTH) [4,5].
Seminomas have seldomly been related with hypercal-
cemia. Less than ten cases have documented this excep-
tional association. Besides two cases related to bone
metastasis, the mechanism of hypercalcemia in semino-
mas has been discussed in two previous reported cases
to be secondary to 1,25(OH)2D3 secretion. The under-
lying mechanism in the rest of the cases was not estab-
lished. In the previous reports PTHrP was not measured
nor related to hypercalcemia. In all of the previous docu-
mented cases, independent of the hypercalcemia related
mechanism, normocalcemia was achieved soon after
definitive treatment was initiated [6-9].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Laboratory measures
Value Basal Post-chemotherapy Range
Glucose (mg/dl) 93 87 (70-100)
Creatinine (mg/dl) 3.7 2.8 (0.6-1.2)
Urea nitrogen (mg/dl) 11 13 (8-23)
MDRD GFR (ml/min) 24.0 37.1 (≥60)
Albumin (g/dl) 3.9 (3.5-5.0)
Calcium (mg/dl) 14.7 9.8 (8.2-10.2)
Phosphorus (pg/ml) 4.1 4.3 (2.3-4.7)
Magnesium (mg/dl) 1.8 2.1 (1.5-2.3)
Potassium (mmol/l) 3.8 4.1 (3.5-5.0)
Urinary calcium (mg/kg/d) 3.2 2.4 (2-4)
Alkaline phosphatase (UI/l) 146 (50-120)
LDH (UI/l) 648 110 (100-200)
AFP (ng/ml) 4.33 3.11 (≤6.0)
β-hCG (uUI/ml) 35.0 (≤3.0)
PTH (pg/ml) <3.0 13.2 (1.5-37)
PTHrP (pg/ml) 35.0 9.0 (14-27)
25(OH)D3 (ng/ml) 22.0 21.0 (>20)
1,25(OH)2D3 (pg/ml) 212.0 8.0 (18-38)
MDRD GFR, modification of diet in renal disease glomerular filtration rate;
LDH, lactate dehydrogenase; APF, alpha-fetoprotein; β –hCG, human chorionic
gonadotropin; PTH, parathyroid hormone; PTHrP, parathyroid hormone related
protein; 25(OH)D3, 25, Hydroxyvitamin D; 1,25(OH)2D3, 1,25-Dihydroxyvitamin D.
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noma and malignant hypercalcemia mediated by 1,25
(OH)2D3 and PTHrP paraneoplastic cosecretion.
Case presentation
A 35-year-old man was referred to the Endocrinology
Division for assessment and management of severe
hypercalcemia related to an abdominal mass. Other-
wise, he had an unremarkable medical history. One
year before admission he noticed a painless hypogastric
abdominal mass. The tumor progressively grew and
two months before admission he developed asthenia,
anorexia, general weakness, constipation, and an unin-
tentional 10 kg weight loss. A month before admission
the appearance of a left inguinal mass finally made him
seek medical attention.
An abdominal ultrasound revealed a 10 × 9 × 7 cm het-
erogeneous (hypoechogenic with hyperechogenic areas)
retroperitoneal mass along with bilateral severe hydrone-
phrosis. Serum creatinine was 2.8 mg/dl with a modifica-
tion of diet in renal disease (MDRD) calculated glomerular
filtration rate (GFR) of 35 ml/min. This consequently
led to an uncomplicated unilateral left nephrostomy.
An abdominal and pelvic enhanced computed tomog-
raphy (CT) confirmed a calcified pelvic mass, along
with multiple retroperitoneal lymphadenopathy (>5 cm
each) (Figure 1). A biopsy was performed and the
histopathology result was consistent with a seminoma.
Chest x-ray revealed “cannon ball” pulmonary metasta-
ses. Lactate dehydrogenase (LDH) was 648 UI/L and
human chorionic gonadotropin was slightly elevated
(35.0 μUI/ml). Alpha-fetoprotein was within its normal
reference value (Table 1). A stage IIIB seminoma wasFigure 1 Pelvic enhanced computed tomography that
shows a 10×9×7 cm mass with heterogeneous density and
calcifications (Arrow).diagnosed and the patient was referred to oncology for
chemotherapy.
Two days before admission he presented nausea, poly-
uria, polydipsia, lethargy, and confusion that led him to
the emergency room. On physical examination he was
hemodynamically stable with a heart rate of 82 per mi-
nute, blood pressure of 130/85 mmHg, a respiratory rate
of 16 per minute, a temperature of 36.3°C and a room-
air oxygen saturation of 97%. An irregular 10 cm ab-
dominal mass was palpated along with bilateral inguinal
adenopathy. The left testicle was not palpable. Serum
calcium was 14.7 mg/dl, albumin 3.9 g/dl, alkaline phos-
phatase 146 UI/l, creatinine 3.7 mg/dl with a MDRD
GFR of 24 ml/min. He also had a mild elevated anion-
gap metabolic acidosis and a urinary calcium of 3.2 mg/
kg/d (240 mg/24 h). Phosphorous, magnesium, potas-
sium, sodium, chlorine, and glucose were normal. PTH
was undetectable, 25-dihydroxyvitamin D was normal,
PTHrP was 35.0 pg/ml, and calcitriol 212 pg/ml (Quest
Diagnostics Nichols, Chantilly, VA) (Table 1). An elec-
trocardiogram showed a shortened QT interval and a
bone scan was negative for metastasis. Calcitonin and
hydration with intravenous saline solution at 250 ml/h
was started. Despite therapy, calcium lowered only to
13.5 mg/dl, but nevertheless his mental status improved.
The patient received four cycles of bleomycin, etoposide
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cium, LDH and alkaline phosphatase returned to normal
values. Both PTHrP and 1,25(OH)2D3 dropped dramatically
to 9.0 pg/ml and to 8.0 pg/ml, respectively (Table 1). At
8 months follow-up, the patient was asymptomatic. CT
scans showed no residual disease and calcium levels have
been consistently normal without medication.
Discussion
This case illustrates, to our knowledge, the first reported
case of malignant hypercalcemia in a patient with semi-
noma related to paraneoplastic cosecretion of PTHrP and
1,25(OH)2D3. Pure seminomas (no non-seminomatous ele-
ments present) account for up to 60% of all testicular germ
cell tumors. They usually affect males between the second
and fourth decade of life, representing 1% of all cancers in
men. Undescended testes (cryptorchidism), as in our pa-
tient, is a risk factor and they are usually associated with a
good prognosis with an overall five-year survival of 95%
and even 80% in intermediate and high-risk patients
[10,11]. Hyercalcemia associated with malignancy has been
well described in both solid and hematologic malignancies
(usually lymphomas) and represent the most common
cause of elevated serum calcium in hospitalized patients
[1]. The four mechanisms by which malignant hypercalce-
mia can occur are: 1) direct osteolytic metastases (20% of
cases), usually related to multiple myeloma and breast
cancer with release of cytokines such as interleukin (IL)-1,
IL-6, IL-8 and activation of nuclear factor kappa beta; 2)
PTH-rP or humoral hypercalcemia (80% of cases) usually
described in nonmetastatic solid tumors (bladder, breast
and squamous cell) and some non-Hodgkin lymphomas; 3)
ectopic PTH secretion with only a few cases reported,
and 4) 1,25(OH)2D3 secretion that accounts for less
than 1% of cases [4,5,12,13].
Usually associated to granulomatous diseases such as
sarcoidosis, tuberculosis, and systemic fungal infections,
among others, calcitriol mediated hypercalcemia has beenTable 2 Reported malignant hypercalcemia in seminomas
Author (*) Ca+ PTH PTHrP 25D 1,2
King [6] 15.4 NS NS NS NS
Metcalfe [7] 15.8 NS NS NS NS
Grote [8] 15.4 10.0 NS 24.0 112
Da Silva [9] 12.7 NL NS NS NS
Da Silva [9] 18.5 NS NS NS NS
Da Silva [9] 20.1 NS NS NS NS
Da Silva [9] 16.4 0.3 NS NS 79
This report 14.7 ≤3.0 35.0 22.0 212
(*) Reference.
Ca+, Calcium (mg/dl); PTH, parathyroid hormone; PTHrP, parathyroid hormone relat
treatment; NS, not stated; NL, normal; NED, not evidence of disease; BEP, bleomycin
CT, chemotherapy.infrequently related to neoplasms [14]. Lymphomas have
been the most common type of malignancy described, and
other kind of tumors, such as disgerminomas, have rarely
been reported [15]. Seminomas have been associated with
malignant hypercalcemia almost anecdotally, with less
than ten cases reported in the literature (Table 2). King
et al. and Metcalfe et al. described the first two cases in
the 70s. In their report, they both associated a seminoma
with a pseudohyperparathyroidism and were not able to
measure neither PTHrP nor vitamin D metabolites. In
both cases, hypercalcemia resolved after definitive treat-
ment with orchiectomy or corticosteroid-radiotherapy
[6,7]. In 1987, Grote and Hainsworth reported the first
case of a seminoma with a calcitriol mediated malignant
hypercalcemia. Baseline calcitriol level was 125 pg/ml,
with a normal PTH, 25-Hydroxyvitamine D and high 24 h
urine calcium. PTHrP was not measured. After the first
chemotherapy cycle, calcitriol concentration fell to 29 pg/
mL and normocalcemia was achieved [8]. In 1992, da Silva
et al. reported seven cases (four new and three previously
described cases) of seminoma associated with malignant
hypercalcemia. With regard to the four new cases, PTH
was normal in three and was not measured in one. PTHrP
and 25-hydroxyvitamin D were not measured in any case
and 1,25(OH)2D3 was measured only in one case with an
initial concentration of 79 pg/mL that decreased to 5 pg/
mL after two cycles of chemotherapy and was associated
afterwards with normocalcemia [9].
On the other hand, PTHrP has never been described in a
patient with a pure seminoma. There are two reported
cases of hypercalcemia associated with non-seminomatous
germ cell tumors (NSGCTs). MacDiarmid et al. in 1995 re-
ported a malignant hypercalcemia associated to an extrago-
nadal NSGCT that was suspected to be probably due to a
humoral hypercalcemia after bone scans were negative.
PTHrP and vitamin D metabolites were not measured [16].
Later on, Sorscher described a patient with severe hypercal-
cemia and a NSGCT with a high PTHrP and a normal5D Tx Ca + after Tx. Outcome
Orchiectomy NL NED 10 mo.
GC + RT NL NED 8 mo.
BEP NL NED 2 yr.
NSCT NL Adenophaty
BEP NL NED 2 mo.
NSCT NL NED 4 mo.
BEP NL Improved after CT
BEP NL NED 8 mo.
ed protein; 25D, 25, Hydroxyvitamin D; 1,25D, 1,25-Dihydroxyvitamin D; Tx,
, etoposide and cisplatinum; NSCT, not specified chemotherapy;
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No measurements of 25-hydroxyvitamin D and 1,25(OH)2
D3 levels were made [17]. In our case, a diagnosis of pure
seminoma was well documented. Baseline serum cal-
cium was elevated, urinary calcium, phosphorous and
25-hydroxyvitamin D were normal, PTH was undetect-
able and calcitriol and PTHrP were elevated. After one
cycle of chemotherapy, normocalcemia was restored and
both, calcitriol and PTHrP dropped to normal levels.
The exact mechanism by which calcitriol is produced
in malignancy remains open to debate. Normally, in the
kidney, 1α-hydroxylase converts 25-hydroxyvitamin D into
the biologically active 1,25(OH)2D3, which is essential for
bone and calcium metabolism/homeostasis. Nevertheless,
1α-hydroxylase has also been described in normal human
tissues such as placenta, skin, gastrointestinal tract, testes,
central nervous system and osteoblasts [18]. More than
twenty granulomatous conditions are known to have en-
hanced 1α-hydroxylation of vitamin D in macrophages and
increased production of active calcitriol causing hypercalce-
mia and/or hypercalciuria [19]. In lymphomas, Hewison
et al., using inmunolocalization, showed stained sections of
spleen that were negative for 1α-hydroxylase in lymphoma
cells, but that were positive in surrounding macrophages
[20]. Nonetheless, Evans et al. showed by reverse tran-
scription polymerase chain reaction that mRNA for
1α-hydroxylase was increased 222-fold in disgermi-
noma cells compared to the surrounding non-ovarian
tissue [21]. The exact mechanism in seminomas has
not been explored. On the other hand, PTHrP is well
recognized to be secreted by a variety of malignancies,
in which there is an uncoupling of bone resorption and
formation and a reduced ability of the kidney to clear cal-
cium with the resultant hypercalcemia [22]. This last effect
on the kidney could be the cause of the normal 24-h urin-
ary calcium reported in our case, when it has been usually
reported to be high in other calcitriol mediated pathologies
[6-9,23]. As well, PTHrP is usually associated with hypo-
phosphatemia due to an increase in urinary phosphorous;
in this case, the concomitant renal failure could have di-
minished this last effect [24]. Interestingly, normocalcemia
has consistently been achieved and sustained, in our case
and in all previous cases, soon after definitive treatment
with chemotherapy, surgery or glucocorticoids [5-8]. In this
way, it is probable that bisphosphonates, denosumab, gal-
lium nitrate, cinacalet and other medications directed to
lower serum calcium could be withheld until definitive
treatment is initiated.
Conclusion
Seminomas have seldom been associated with hypercalce-
mia. We have described the case of a patient with a semi-
noma and malignant hypercalcemia related to cosecretion
of 1,25(OH)2D3 and PTHrP. After successful treatment,calcium, PTHrP and 1,25(OH)2D3 returned to normal
values. The exact mechanism by which seminomas secrete
1,25(OH)2D3 still remains to be elucidated.
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